Background: Second-line antiretroviral therapy (ART) was
introduced in Henan Province in 2009. Most studies of this treatment
strategy focus on drug resistance and treatment failure, not on
mortality. To investigate the survival and effectors of mortality among
patients with human immunodeficiency virus/acquired immunodeficiency
syndrome (HIV/AIDS) who switched to second-line antiretroviral therapy
(ART) in rural China. We conducted a retrospective cohort study of
people living with HIV (PLHIV) who switched to second-line ART between
May 1, 2010 to May 1, 2016. The data were analyzed using the
Kaplan–Meier method and Cox proportional hazards models. Among 3331
PLHIV who were followed for 26988 person-years, 508 (15.3%) died and
the mortality rate was 1.88/100 person-years. After adjusting for
confounding factors multivariable Cox proportional hazards regression
identified female (HR, 0.66; 95%CI, 0.55–0.79), age >50
years (HR, 2.69; 95%CI, 2.03–3.56), sig/window (HR, 1.26; 95%CI,
1.04–1.52) , educational status >6 years (HR, 0.78;
95%CI, 0.65–0.94), Chinese medicine(CM) (HR, 0.75; 95%CI,
0.52–0.96), liver injury (HR, 1.58; 95%CI, 1.19–2.10), CD4+ T cell
count <200 cells/µl (HR, 1.94; 95%CI, 1.47-2.55), and CD4+ T
cell count 200-350 cells/µl (HR, 1.37; 95%CI, 1.03–1.82) as
independently variables associated with mortality. Conclusions:
Our retrospective cohort study indicates that mortality among PLHIV who
switched to second-line ART was lower compared with most other studies.
However, the limitations of a retrospective cohort may have biased the
data, so prospective studies should be carried out to confirm our
primary results. The results of our study suggest that Chinese medicine
therapy shows potential as a treatment for PLHIV.